Sign Up Now!
OrganoidXplore™: The first large panel based Organoid screening service
What is OrganoidXplore?
For a limited time only, advance your next-generation therapeutic programs with unprecedented cost savings on OrganoidXplore™ — our enhanced platform featuring 247 comprehensively characterized organoid models optimized for cutting-edge ADCs, targeted therapies, and precision oncology approaches.
Fast-track your oncology drug candidate development with results in just 4-6 weeks. This assay-ready service leverages our semi-automated workflow to deliver rapid, data-driven insights that keep your research ahead of the curve.
At the heart of this premier service is an extensive biobank of thoroughly characterized PDO and PDXO models spanning 14 cancer types with clinically relevant mutational profiles. The platform provides detailed measurements of drug responses in both tumor and normal organoids, facilitates exploration into new cancer indications backed by validated targets, and supports advanced biomarker discovery—all with comprehensive molecular characterization including RNAseq, WES, and TAA expression profiling.
Limited-Time Promotional Offer
Exclusive Pricing Benefits:
- 30% discount per model, per compound
- 50% cost share opportunity on Standard of Care compounds
- Rolling submissions accepted
Key Dates:
- Registration Deadline: May 8th, 2026
- Screen Execution: May 25th, 2026
- Results Delivery: 6 weeks post-execution
Available in Netherlands or China facilities
Secure Your Spot Now
Don't miss this limited-time opportunity. Registration closes May 8th, 2026.
Why Choose OrganoidXplore™?
| Key Area | Noteworthy Benefits |
|---|---|
| Unmatched Scale & Diversity | Access 247 well-characterized PDO and PDXO models spanning 14 cancer types with diverse genetic backgrounds including KRAS, BRAF, EGFR, BRCA1/2, and other clinically relevant mutations. |
| Multiple Panel Options | Choose from Large Panel Screen (247 models), KRAS Panel, Lung Panel, CRC Panel, or Flexible Panel (20+ custom model selection). All panels eligible for 30% promotional discount. |
| Data Reliability | Depend on rigorously validated and quality-assured organoid models—SNP verified, mycoplasma tested, and characterized with standard of care agents. Validated assay performance with Z-factor >0.5 and CV <15%. |
| 14 Cancer Type Models | Explore and test efficacy across colorectal, lung, pancreatic, breast, ovarian, gastric, head and neck, cervical, esophagus, bladder, gallbladder, liver, melanoma, and mesothelioma. |
| Rich Molecular Profiling | Every model includes RNAseq, WES data, and TAA expression profiling with 60+ validated IHC assays—essential for ADC development and patient stratification. |
| Comprehensive Analysis | Investigate off-target effects with matched normal/disease pairs, enabling thorough comparative safety analysis. |
| Seamless In Vivo Transition | Access corresponding PDX models from our extensive biobank to validate organoid findings and advance lead candidates with confidence. Proven high correlation between PDXO and PDX response. |
| Clinical Relevance | Organoid predictions correlate with patient clinical response: 84-100% sensitivity, 69-100% specificity across multiple cancer types in published studies. |
Accelerated Progress
Fast-Track Your Screen: 247 models, results in 4-6 weeks. Benefit from a streamlined 5-day incubation time, facilitating timely results and accelerating your research timelines. Our semi-automated workflow ensures accuracy and reproducibility across runs with state-of-the-art liquid handlers, delivering consistent Z-factors >0.5 and CVs <15%.
In-Depth Customer Report
Receive a comprehensive report featuring:
- 9-point dose-response curves for every model tested
- IC50 values with confidence intervals
- Study design and methodology details
- Control performance metrics (Z-factor, CV%)
- Raw data files for independent analysis
- Model characterization data (mutations, expression profiles)
- Comparison to SOC agents (when applicable)
Flexible Add-On Services to Maximize Your Investment
Biomarker Identification & Patient Stratification: Integrate differential expression analysis between responders and non-responders. Leverage our RNAseq and WES data to identify predictive biomarkers and stratify patient populations for clinical development.
Mechanism of Action Studies: Opt for high-content imaging to visualize ADC penetration, measure bystander killing effects, and assess antibody binding, internalization, and co-localization—critical for ADC optimization.
Drug Combination Studies: Explore enhanced therapeutic potential through combination studies, opening new avenues for synergistic treatment strategies.
Matched In Vivo Validation: Seamlessly transition to efficacy studies with corresponding PDX models from our biobank. Validate organoid predictions with PK/PD profiling and in vivo efficacy to support clinical translation.
ADC Stability Analysis: Assess stability in plasma/blood via LC-MS and ELISA. Monitor DAR with LC-HRMS over time and evaluate payload release under physiological conditions.
Proven Success Across Therapeutic Modalities
Targeted Therapies: Validated with KRAS G12C inhibitors (Sotorasib), RAS-ON inhibitors (Daraxonrasib), and molecular glues (CC-885)
ADC Development: Comprehensive characterization with TOP1-targeting ADCs (Datopotamab deruxtecan, Trastuzumab deruxtecan) and 10+ common payloads
Chemotherapies: Biomarker discovery and patient stratification across diverse genetic backgrounds
